Clinical Trials Logo

Metastatic Cancer clinical trials

View clinical trials related to Metastatic Cancer.

Filter by:

NCT ID: NCT04396886 Completed - Metastatic Cancer Clinical Trials

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Start date: February 27, 2020
Phase: Phase 2
Study type: Interventional

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).

NCT ID: NCT04390724 Recruiting - Metastatic Cancer Clinical Trials

Optimizing Y90 Therapy for Radiation Lobectomy

Start date: July 17, 2020
Phase:
Study type: Observational

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

NCT ID: NCT04380103 Recruiting - Colorectal Cancer Clinical Trials

A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

Start date: April 26, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of safety and efficacy.

NCT ID: NCT04355858 Recruiting - Breast Cancer Clinical Trials

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

MULAN
Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.

NCT ID: NCT04330664 Active, not recruiting - Metastatic Cancer Clinical Trials

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Start date: April 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

NCT ID: NCT04319757 Recruiting - Solid Tumor Clinical Trials

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Start date: May 19, 2020
Phase: Phase 1
Study type: Interventional

ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.

NCT ID: NCT04317651 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

SPECIALK
Start date: May 16, 2019
Phase:
Study type: Observational

This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.

NCT ID: NCT04313868 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

GEN2 Directed Cancer Immunotherapy Trial

GEN2
Start date: June 13, 2014
Phase: Phase 1
Study type: Interventional

Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary & metastatic liver tumors.

NCT ID: NCT04295863 Recruiting - Metastatic Cancer Clinical Trials

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Start date: June 25, 2020
Phase: Phase 1
Study type: Interventional

A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.

NCT ID: NCT04260802 Recruiting - Cancer Clinical Trials

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Start date: October 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will investigate OC-001 as monotherapy, and in combination with an anti-Programmed Cell Death Protein-1 (PD-1) or anti-Programmed Cell Death Ligand-1 (PD-L1) Antibody inhibitor, in various cancer types